JP2007538054A5 - - Google Patents

Download PDF

Info

Publication number
JP2007538054A5
JP2007538054A5 JP2007517257A JP2007517257A JP2007538054A5 JP 2007538054 A5 JP2007538054 A5 JP 2007538054A5 JP 2007517257 A JP2007517257 A JP 2007517257A JP 2007517257 A JP2007517257 A JP 2007517257A JP 2007538054 A5 JP2007538054 A5 JP 2007538054A5
Authority
JP
Japan
Prior art keywords
substituents
substituted
alkoxy
alkyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007517257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538054A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/052281 external-priority patent/WO2005110413A2/en
Publication of JP2007538054A publication Critical patent/JP2007538054A/ja
Publication of JP2007538054A5 publication Critical patent/JP2007538054A5/ja
Pending legal-status Critical Current

Links

JP2007517257A 2004-05-19 2005-05-18 肥満および関係する病気の予防または治療のためのn−スルファモイル−n′−アリールピペラジンを含有する薬剤 Pending JP2007538054A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57223604P 2004-05-19 2004-05-19
EP04102210 2004-05-19
PCT/EP2005/052281 WO2005110413A2 (en) 2004-05-19 2005-05-18 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Publications (2)

Publication Number Publication Date
JP2007538054A JP2007538054A (ja) 2007-12-27
JP2007538054A5 true JP2007538054A5 (enExample) 2008-04-10

Family

ID=34969508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517257A Pending JP2007538054A (ja) 2004-05-19 2005-05-18 肥満および関係する病気の予防または治療のためのn−スルファモイル−n′−アリールピペラジンを含有する薬剤

Country Status (11)

Country Link
EP (1) EP1750712A2 (enExample)
JP (1) JP2007538054A (enExample)
CN (1) CN1997370B (enExample)
AU (1) AU2005244450B2 (enExample)
BR (1) BRPI0510137A (enExample)
CA (1) CA2567166A1 (enExample)
IL (1) IL178903A0 (enExample)
MX (1) MXPA06013299A (enExample)
NO (1) NO20065835L (enExample)
RU (1) RU2395503C2 (enExample)
WO (1) WO2005110413A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
ES2349160T3 (es) * 2006-01-23 2010-12-28 F. Hoffmann-La Roche Ag Derivados de la ciclohexil sulfonamida con actividad frente a los receptores h3.
CN101801375B (zh) 2007-01-25 2014-01-01 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法
HUE025647T2 (en) * 2009-04-22 2016-04-28 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
RU2445963C2 (ru) * 2010-07-09 2012-03-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая противодиабетическая композиция
EP3587406B1 (en) 2013-03-13 2021-01-27 Forma Therapeutics, Inc. 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
GB201410817D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748125A (en) * 1954-04-26 1956-05-29 American Cyanamid Co 1-substituted-4-sulfamylpiperazine and method of preparing the same
FR2030116A1 (en) 1969-01-02 1970-10-30 Sandoz Sa Herbicide compositions and prepn
US3709677A (en) 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
SU1646258A3 (ru) * 1989-02-08 1996-02-10 Институт биохимии Литовской АН 5-аминонафталин-1-сульфамиды в качестве детектируемых групп субстратов для флюоресцентного анализа пептидаз
DE4025387A1 (de) 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
JPH09504508A (ja) * 1993-09-28 1997-05-06 チバ−ガイギー アクチエンゲゼルシャフト 殺虫剤及び殺ダニ剤としてのアクリル化スルホンアミド
PT958287E (pt) * 1997-01-23 2002-12-31 Hoffmann La Roche Inibidores de sulfamida-metaloprotease
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
KR20040090979A (ko) * 2002-03-13 2004-10-27 얀센 파마슈티카 엔.브이. 히스톤 데아세틸레이즈의 신규한 억제제
HRP20041154A2 (en) * 2002-06-06 2005-06-30 Boehringer Ingelheim Pharmaceuticals Inc. SUBSTITUTED 3-AMINO-THIENO[2,3-b] PYRIDINE-2-CARBO
WO2005005382A2 (en) * 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
RU2408587C2 (ru) 2004-08-24 2011-01-10 Астразенека Аб Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов

Similar Documents

Publication Publication Date Title
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
ES2532210T3 (es) Métodos para el tratamiento concomitante de teofilina y febuxostat
US10604502B2 (en) Substituted 5-cyanoindole compounds and uses thereof
CN110831927B (zh) 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物
EA022301B1 (ru) Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение
TW201036972A (en) Compounds and uses thereof
EA024984B1 (ru) Производные 6-циклоалкил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве ингибиторов pde9a
ES2802977T3 (es) Compuesto para la modulación inmunológica, uso del mismo y composición farmacéutica que lo comprende
JP2009506014A5 (enExample)
RU2512547C2 (ru) Содержащее конденсированную кольцевую структуру производное и его применение в медицине
JP2007538054A5 (enExample)
TW200927127A (en) Agent for overcoming resistance to anti-cancer agent
AU2013318672B2 (en) Means and method for treating solid tumours
KR20140129164A (ko) 히스톤 데아세틸라아제 억제제 및 파조파닙의 조합물 및 이의 용도
JP2009502770A5 (enExample)
Sharma et al. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase iv inhibitors
TW201100422A (en) New crystalline form of pemirolast
JP2016505017A (ja) 2−((1r,4r)−4−(4−(5−(ベンゾオキサゾール−2−イルアミノ)ピリジン−2−イル)フェニル)シクロヘキシル)酢酸のメグルミン塩形態、およびdgat1阻害剤としてのそれらの使用
KR100280240B1 (ko) 호산구 주화성 억제제
CN103435562B (zh) 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
WO2001032658A1 (en) Polyazanaphthalene compound and medicinal use thereof
CN117736193A (zh) 一种氘代稠环化合物及其制备方法与用途
CN104327046B (zh) 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
CN110194769B (zh) 一类hdac、cdk双靶点抑制剂及其制备方法与应用
JP6010614B2 (ja) 血清尿酸を低下させるための[1,2,4]チアジアジン1,1−ジオキサイド化合物